PE20210044A1 - Compuestos para el tratamiento de trastornos dependientes de cinasas - Google Patents
Compuestos para el tratamiento de trastornos dependientes de cinasasInfo
- Publication number
- PE20210044A1 PE20210044A1 PE2020001120A PE2020001120A PE20210044A1 PE 20210044 A1 PE20210044 A1 PE 20210044A1 PE 2020001120 A PE2020001120 A PE 2020001120A PE 2020001120 A PE2020001120 A PE 2020001120A PE 20210044 A1 PE20210044 A1 PE 20210044A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- treatment
- kine
- dependent disorders
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describen en la presente compuestos de la Formula I'. Los compuestos de la Formula I' inhiben, regulan y/o modulan el receptor de cinasa, particularmente las vias de transduccion de senales de Axl y Mer relacionadas con los cambios en las actividades celulares mencionados anteriormente, las composiciones que contienen estos compuestos y los metodos para usarlos para el tratamiento de enfermedades y afecciones dependientes de cinasas. La presente invencion tambien proporciona metodos para la confeccion de compuestos mencionados anteriormente, y composiciones que contienen estos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622629P | 2018-01-26 | 2018-01-26 | |
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015289 WO2019148036A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210044A1 true PE20210044A1 (es) | 2021-01-08 |
Family
ID=65409542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001120A PE20210044A1 (es) | 2018-01-26 | 2019-01-25 | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (es) |
| EP (1) | EP3743068A1 (es) |
| JP (2) | JP7307733B2 (es) |
| KR (1) | KR102759973B1 (es) |
| CN (1) | CN112312909B (es) |
| AU (1) | AU2019212719B2 (es) |
| BR (1) | BR112020015199A2 (es) |
| CA (1) | CA3088127A1 (es) |
| CL (1) | CL2020001930A1 (es) |
| CO (1) | CO2020010467A2 (es) |
| CR (2) | CR20250117A (es) |
| IL (2) | IL276028B2 (es) |
| MA (1) | MA51672A (es) |
| MX (2) | MX2020007759A (es) |
| PE (1) | PE20210044A1 (es) |
| PH (1) | PH12020551059A1 (es) |
| SA (1) | SA520412488B1 (es) |
| SG (1) | SG11202006945PA (es) |
| UA (1) | UA128348C2 (es) |
| WO (1) | WO2019148036A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| MA51673B1 (fr) * | 2018-01-26 | 2025-10-31 | Exelixis, Inc. | Composés pour le traitement des troubles dépendants de kinases |
| SG11202006945PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| WO2021180006A1 (zh) * | 2020-03-10 | 2021-09-16 | 南京明德新药研发有限公司 | 乙烯基取代吡啶类化合物 |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN117164527A (zh) * | 2022-05-25 | 2023-12-05 | 大连理工大学 | 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| SK284073B6 (sk) | 1996-04-12 | 2004-09-08 | Warner-Lambert Company | Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BRPI0412262A (pt) | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
| US8293897B2 (en) * | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20130022983A1 (en) | 2009-10-26 | 2013-01-24 | Externautics S.P.A. | Colon and Rectal Tumor Markers and Methods of Use Thereof |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| EP2493917B8 (en) | 2009-10-26 | 2020-03-04 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| WO2012006960A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| JP6461800B2 (ja) | 2012-10-04 | 2019-01-30 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法 |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| EP3008086A2 (en) | 2013-06-14 | 2016-04-20 | Externautics S.p.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| BR112016024672A2 (pt) | 2014-04-25 | 2021-02-02 | Exelixis, Inc | método para o tratamento de adenocarcinoma de pulmão |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN110437145A (zh) | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CA3086522A1 (en) | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Carbamate and urea compounds as multikinase inhibitors |
| SG11202006945PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
-
2019
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
- 2019-01-25 KR KR1020207024577A patent/KR102759973B1/ko active Active
- 2019-01-25 BR BR112020015199-8A patent/BR112020015199A2/pt unknown
- 2019-01-25 UA UAA202005478A patent/UA128348C2/uk unknown
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
- 2019-01-25 IL IL276028A patent/IL276028B2/en unknown
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 CN CN201980021547.0A patent/CN112312909B/zh active Active
- 2019-01-25 AU AU2019212719A patent/AU2019212719B2/en active Active
- 2019-01-25 CA CA3088127A patent/CA3088127A1/en active Pending
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/en not_active Ceased
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 CR CR20250117A patent/CR20250117A/es unknown
- 2019-01-25 EP EP19704968.7A patent/EP3743068A1/en active Pending
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
-
2020
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 SA SA520412488A patent/SA520412488B1/ar unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP7596427B2/ja active Active
- 2023-05-03 IL IL302626A patent/IL302626B2/en unknown
- 2023-06-13 US US18/334,113 patent/US12195475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002398A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas (divisional de solicitud no. 202001931) | |
| PE20210044A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
| MX2020007383A (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47. | |
| MX2020001103A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| ECSP21080096A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra | |
| ECSP088306A (es) | Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
| CR8825A (es) | Metabolitos de indolilalquilamina como ligandos 5- hidroxitriptamina-6 | |
| EA202091789A1 (ru) | Соединения для лечения киназозависимых расстройств | |
| EA202091790A1 (ru) | Соединения для лечения киназозависимых расстройств |